Assembly Biosciences (NASDAQ:ASMB) Shares Gap Up – Here’s What Happened

Assembly Biosciences, Inc. (NASDAQ:ASMB)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $30.01, but opened at $32.88. Assembly Biosciences shares last traded at $32.8750, with a volume of 4,670 shares trading hands.

Assembly Biosciences News Summary

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $50 price target, implying substantial upside from recent trading levels. The firm raised its FY2026 EPS estimate to $2.28 from $1.90 and improved its Q3 2026, Q1 2027, Q2 2027, Q3 2027 and FY2027 forecasts. HC Wainwright analyst estimates
• Positive Sentiment: Analysts collectively rate Assembly Biosciences a Moderate Buy, while HC Wainwright separately reiterated its Buy recommendation. Consensus analyst rating HC Wainwright Buy rating
• Positive Sentiment: Zacks cited positive earnings-estimate revisions and momentum factors, noting that the average Wall Street price target suggests approximately 40.7% potential upside. Zacks cautioned that price targets are not always reliable predictors. Assembly Biosciences analyst price target
• Neutral Sentiment: The latest momentum-focused coverage presents ASMB as a potential pick for momentum investors, reinforcing the stock’s recent strength but offering no new clinical, regulatory or operating catalyst. Assembly Biosciences momentum coverage
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS estimate to $3.19 from $3.69 and trimmed its Q4 2027 forecast to $1.63 from $1.66. These cuts suggest some uncertainty around future quarterly profitability, despite the firm’s overall upward revisions and Buy rating.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a research report on Tuesday. Guggenheim restated a “buy” rating and set a $43.00 price target on shares of Assembly Biosciences in a research report on Thursday, May 28th. Wall Street Zen cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Finally, Mizuho set a $45.00 target price on Assembly Biosciences and gave the company an “outperform” rating in a research report on Monday, June 15th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.00.

Assembly Biosciences Stock Down 0.9%

The stock has a 50-day moving average of $26.88 and a 200 day moving average of $27.55. The stock has a market cap of $682.67 million, a PE ratio of 32.87 and a beta of 1.10.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%.The company had revenue of $13.37 million during the quarter, compared to analysts’ expectations of $8.60 million. Research analysts forecast that Assembly Biosciences, Inc. will post 2.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Assembly Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of ASMB. Bank of America Corp DE boosted its holdings in Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 3,319 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Assembly Biosciences during the 4th quarter worth approximately $147,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at approximately $228,000. Virtus Investment Advisers LLC purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at approximately $251,000. Finally, Engineers Gate Manager LP acquired a new position in Assembly Biosciences in the fourth quarter valued at approximately $353,000. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.